Search Results
Dec 08, 2025, 10:30 ET Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
azacitidine, and the result for that endpoint was 0.913 (90% confidence interval [CI]: 0.78, 1.07).In patients with MDS (n=22), the complete response (CR) rate was 22.7% and overall response rate was 50%.Among patients who were dependent on red blood cell (RBC) transfusions at baseline (n=13),
More news about: Taiho Oncology
Dec 08, 2025, 08:31 ET QuesTek Wins First Place in AM Bench 2025 Challenge for Predicting Phase Transformations in Fe-Cr-Ni Alloys
qualification."About the ChallengeThe challenge focused on predicting the sequence of phases that form during rapid solidification in Fe-Cr-Ni alloys with different Cr/Ni ratios. These alloys serve as a model system for many stainless steels, and are particularly relevant to AM because the process involves
More news about: QuesTek Innovations
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose
More news about: CARsgen Therapeutics
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
efficacy across dose levels 400–1200 μg/kg (n=40).ORR reached 82.5%, with ≥CR at 52.5%, ≥VGPR at 72.5%, and MRD negativity at 80.0%.At 800 μg/kg, ORR and ≥CR were 90.9% and 63.6%, respectively.Robust activity in difficult-to-treat RRMM
More news about: Leads Biolabs
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
10 patients with EMD and 77.8% in 9 patients who had previously received anti-BCMA and/or anti-GPRC5D therapies.Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=4).Potent
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose
More news about: CARsgen Therapeutics
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
with 82.7% of patients in this arm seeing a complete response (CR) to treatment versus 49.8% among those who received R2 alone. Participants who received epcoritamab plus R2 also showed a significantly longer duration of response and CR. The results were consistent across all subgroups analyzed.Additionally,
More news about: American Society of Hematology
Dec 07, 2025, 04:21 ET CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10⁻⁵ threshold. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively.
More news about: CARsgen Therapeutics
Dec 05, 2025, 08:00 ET Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
response evaluable (n=30), the overall response rate (ORR) was 87 percent, and the rate of complete remissions with full or partial hematologic recovery (CR/CRh) was 43 percent.Among patients receiving DXA scans across lines of therapy (n=56), 21 percent had low bone density at baseline. In this population,
More news about: Blueprint Medicines, a Sanofi company
Dec 04, 2025, 22:20 ET TELUS announces pricing of US$ and CAD$ junior subordinated notes offerings
2046, 4.40% Notes, Series CL due April, 2043, 4.70% Notes, Series CW due March, 2048, 2.85% Notes, Series CAF due November, 2031 and 4.75% Notes, Series CR due January, 2045 (the "Tender Offer"). TELUS has the right to increase, decrease or waive the Maximum Purchase Amount, in its sole discretion. TELUS
More news about: TELUS Corporation
Dec 04, 2025, 09:05 ET DOJ, FDA-OCI Prosecutions of Illegal HCG Sales Expose Potential Dangers of Unlawful Pharmacy Compounding, Warns NuCare Pharmaceuticals
569-8633Source:1. United States v. Kawa et al., Case No. 3:25-cr-00091 (Indiana), prosecuted by Acting U.S. Attorney M. Scott Proctor and Assistant U.S. Attorney Luke N. Reilander.United States v. Cosie, Case No. 3:23-cr-00057 (Florida), prosecuted by U.S. Attorney Roger Handberg and Assistant
More news about: NuCare Pharmaceuticals
Dec 04, 2025, 09:03 ET Top Crunch Franchisee CR Fitness Goes Big with Four Texas One-Day Cyber Sale Events
reach their fitness goals."Bringing our one-day Cyber Sale to four Texas locations at once shows just how fast CR Fitness is growing across the state," said Tony Scrimale, CEO of CR Fitness Holdings. "We're expanding our footprint to make the Crunch experience accessible to more communities than
More news about: CR Fitness Holdings, LLC.
Dec 04, 2025, 08:19 ET TELUS Announces Cash Tender Offers for Seven Series of Debt Securities
+604.75% Notes, Series CR dueJanuary, 2045C$400,000,000
More news about: TELUS Corporation
Dec 04, 2025, 06:50 ET 科倫博泰與Crescent Biopharma 達成合作，共同開發及商業化新型腫瘤治療手段
科倫博泰首席執行官葛均友博士表示：「很高興與Crescent就兩款創新資產CR-001及SKB105達成合作。此次合作通過引入CR-001進一步補充與強化了科倫博泰差異化的腫瘤治療管線，同時助力推進SKB105的全球開發進程，提升其潛在的商業價值並擴展公司的全球合作網絡。這一創新的全球合作模式有效地整合了雙方的優勢資源，以共同探索 SKB105 與 CR-001 在腫瘤治療領域的新型單藥及聯合用藥策略。通過依托中國豐富的臨床資源與高效的執行效率，我們將在嚴格遵循國際最高標準的前提下加速臨床開發，相信此次合作釋放的強大協同效應，將最大化這兩款候選藥物在中國及全球市場的治療潛力。」Crescent首席執行官Joshua
More news about: 四川科倫博泰生物醫藥股份有限公司
Dec 03, 2025, 19:00 ET High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
received MVR-T3011 at doses of 2x109 PFU, the CR at any time, 3-month and 6-month CRR was 71.4%, and among 5 evaluable patients with BCG-unresponsive CIS (with or without Ta/T1) who received MVR-T3011 at doses of 1x1010 PFU, the CR at any time, 3-month and 6-month CRR was 100%.
More news about: ImmVira
Dec 03, 2025, 10:20 ET Kennametal Recognized by Newsweek as One of America's Most Responsible Companies
View Kennametal's fiscal year 2025 Corporate Responsibility (CR) report.About KennametalWith over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity
More news about: Kennametal Inc.
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
criteriaComplete response (CR) rate was 77.6% (38/49 patients) Of these, 33/38 patients achieving CR remain in CR as of the data cutoff; the 5 patients who did not remain in CR included 2 patients with progressive disease, 2 patients with Grade 5 AEs which occurred during CR, and one censored
More news about: ADC Therapeutics SA
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
87.7]; P<.0001.1 Among patients who were treated with E+R2, 74.5% achieved a complete response (CR) (n=95% CI: 68.5, 79.8) compared to a 43.3% CR rate among patients treated with R2 (n=95% CI: 37.0, 49.7).1Grade 3/4 treatment emergent adverse
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
were limited to Grade 1–2 and no tumor lysis syndrome was observed. Preliminary efficacy was encouraging, with ORR of 77.8% and CR rate of 66.7% at DL1 and both ORR and CR of 100% at DL2, with median duration of response not reached. These early results suggest rituximab may not be required to achieve
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 07:00 ET Q32 Bio Sells Complement Inhibitor ADX-097
science from the University of Colorado Anschutz Medical Campus. Beyond ADX-097, discovery and earlier development efforts include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications as well as potential utility in a broad range of other indications,
More news about: Q32 Bio
Nov 28, 2025, 03:34 ET Roast CCx Hosts French Consul General for an Indo-French Culinary Exchange in Hyderabad
multi-outlet café brands, known for its uncompromising focus on quality, craft, and specialty coffee. Entirely bootstrapped and valued at over ₹250 Cr, Roast CCx is built on a product-first philosophy—doing the classics right, from a clean, honest cup of coffee to globally inspired comfort food. Its
More news about: Roast CCx
Nov 27, 2025, 14:00 ET Citrix Latam anuncia licenciamento baseado em nuvem
do LAS. A empresa já disponibiliza suporte ao novo método em soluções amplamente utilizadas, como Citrix Virtual Apps and Desktops (em versões LTSR e CR), Provisioning (PVS) e tipos específicos de licença para NetScaler.O novo modelo de assinatura (subscrição) das soluções Citrix também ganha protagonismo
More news about: Citrix Latam
Nov 25, 2025, 17:31 ET Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight
approval. On August 18, 2025, the company resubmitted its NDA for elamipretide in Barth syndrome after the FDA's May complete response letter (CR). That CR had not rejected efficacy but pressed Stealth to resolve manufacturing deficiencies and strengthen commitments around a post-marketing trial.
More news about: DelveInsight Business Research, LLP
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
a.m. ESTHigh VGPR/CR rates with pirtobrutinib plusvenetoclax in previously treated Waldenström macroglobulinemia: Resultsfrom a multicenter Phase
More news about: Eli Lilly and Company